Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa

South African Medical Journal

Volumn 97, Issue 4, 2007, Pages 273-279

  Brink, Adrian ^a   Moolman, G J Johan ^b   Cruz da Silva, Mark ^a   Botha, Maria ^a   Badenhorst, L ^c   Botha, F ^c   Breuning, S ^c   Budavari, S ^c   Elliott, G ^c   Gove, E ^c   Heney, C ^c   Henning, M ^c   Kahn, S ^c   Loxton, R ^c   Marcus, L ^c   Mennen, M ^c   Miller, N ^c   Peer, A K ^c   Pillay, K ^c   Schoeman, P ^c   Senekal, M ^c   Smith, P ^c   Smit, J ^c   Swart, W ^c   van Greune, J ^c   van Wyk, J ^c   van Greunen, G ^c   van Rensburg, C ^c   van Rensburg, M ^c   van Rensburg, O ^c   Weldhagen, G ^c   more..

^a Ampath Trust   (South Africa)

^b LANCET LABORATORIES   (South Africa)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FUSIDIC ACID; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOOD CULTURE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ESCHERICHIA COLI; GEOGRAPHY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIVATE HOSPITAL; PSEUDOMONAS AERUGINOSA; SENSITIVITY ANALYSIS; SOUTH AFRICA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; HOSPITALS, PRIVATE; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SOUTH AFRICA; STAPHYLOCOCCUS AUREUS;

EID: 34247250732     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Elliott E, Brink AJ, van Grearre J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with extended-spectrum β-lactamase. Clin Infect Dis 2006; 42: e95-98.
2. Beekman SE, Heilmann KP, Richter SS, et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A β-haemolytic streprococci in 2002-2003. Result of the multinational GRASP surveillance program. Int J Antimicrob Agents 2005; 25:148-156.
3. Bell JM, Turnidge JD, Jones RN and the SENTRY Asia-Pacific participants. Prevalence of extended-spectrurn β-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: Results from the SENTRY antimicrobial su-efflance program, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 3989-3993.
4. Bell JM, Turnidge JD and the SENTRY APAC participants. High prevalence of oxacillin-resistant Staphylacoccus aureus isolates from hospitilized patients in Asia-Pacific and South Africa: Results from the SENTRY antimicrobial surveillance program, 1998 to 1999. Antimicrob Agents Chemother 2002; 46: 879-881.
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth informational supplement M100-S15. Wayne, Penn.: Clinical and Laboratory Standards Institute, 2005.
6. Jarlier V, Nicolas MH, Fournier G, et al. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1998; 10: 867-878.
7. European Antimicrobial Resistance Surveillance System (EARSS). Resistance in Invasive Escherichia coli Isolates in Europe in 2004, EARSS Annual Report 2004. http://www.rivm.nl/earss/images/ earssannualreport2004webversie_tcm61_25345.pdf (last accessed 7 August 2006).
8. Pitout JDD, Nordmarm F, Laupland KB, et al. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases, (ESBLs) in the community. J Antimicrob Chemother 2005, 56: 52-89.
9. Bell JM, Walters L and the SENTRY Asia-Pacific group. High rates of multi-vasistance in bacteraemic Escherichia coli. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, Calif., 2002). Abstract C2-314. Washington, DC: American Society for Microbiology, 2002.
10. Moolmon GJJ, Jankowitz CE, Bezuidenhout S, et al. Beta-lactamases in Enterobacteriaceae - an ever-present threat. S Afr Med J 2006; 96: 331-334.
11. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45:183-189.
12. Saurina G, Quale JM, Manikal VM, et al. Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns. J Antimicrob Chemother 2000; 45: 895-898.
13. De Gheldre Y, Struelens MJ, Glupczynski Y, et al. National epidemiologic surveys of Enterobacter aerogenes in Belgian hospitals from 1996 to 1998. Journal Clinical Microbiology 2001; 39: 889-896.
14. Kang C, Kim S, Park WB, et al. Bloodstream infections caused by Enterobacter species: Predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004; 39: 812-818.
15. Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005; 11: 68-74.
16. Bell JM, Walters L, Turnidge JD and the SENTRY Asia-Pacific group. Rapidly emerging carbapenem-resistance among hospitalized patients in the SENTRY Asia-Pacific region. In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004. Abstract C2-1352. Washington, DC: American Society for Microbiology, 2004.
17. Turnidge JD, Bell JM and the SENTRY Asia-Pacific group. Prevalence of non-multiresistant o-illin-resistant Staphylococcus aureus in the SENTRY Asia-Pacific region, 1998-2003. In: Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004. Abstract C2-2005. Washington, DC: American Society for Microbiology, 2005.
18. Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST program, 2004). Diagn Microbial Infect Dis 2005; 52:215-227.
19. Sader HS, Jones RN, Dowzicky MJ, et al. Antimicrobial activity of tigecycline against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-208.
20. Pitout JDD, Reisbig MD, Venter EC, et al. Modification of the double disk test for detection of Enterobacteriaceae producing extended-spectrum and AmpC β-lactamases. J Clin Microbiol 2003; 41: 3933-3935.
21. Potz NAC, Colman M, Warner M, et al. False-positive extended-spectrum, β-lactamase test for Klebsiella oxytoca strains hyper producing K1 β-lactamase. J Antimicrob Chemother 2004; 53: 545-547.